AMS Strengthens Senior Management Team

Aug 3, 2010

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

RNS Number : 4002Q
Advanced Medical Solutions Grp PLC
03 August 2010

3 August 2010


Advanced Medical Solutions Group plc

(“AMS” or “the Company”)


AMS Strengthens Senior Management Team


Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, announces that it has strengthened its senior management team with key appointments.


Clare Holden has been appointed Vice President of Research and Development.  Clare has over 20 years of process and new product development experience with global organisations such as Smith & Nephew where her last position was as Vice President of New Product Development for their Hull based Wound Management Division. Most recently, Clare was Head of Project Transformations at Siemens’ Automation & Drives Division in Manchester.


In addition, Steve Platt joins as General Manager of AMS’s new world class Winsford facility.  Steve brings 16 years of experience in industrial manufacturing and production with multinational organisations including Toyota Manufacturing (UK), JCB Transmissions, RWD Technologies and, most recently, Nilfisk Advance.  He has a proven track record formaximising business performance through the implementation of lean project management techniques, including green field site responsibilities.


Chris Meredith, COO of Advanced Medical Solutions commented:


“We are delighted to announce these latest additions to our senior management team, strengthening our research and development and general operational functions. The appointments follow on from the appointments earlier in the year of Brian Dowd, who joined us from Covidien to head up our US Commercial team, and Dr. Andrew Garland, who joined us from 3M to head our European Commercial Team.


“The additions add experience and enthusiasm to our existing team, as we develop our infrastructure to take the Company through the next exciting period of growth and realise the opportunities open for our innovative product portfolio.


ends –


For further information, please visit or contact:


Advanced Medical Solutions Group plc

Don Evans, Chief Executive Officer                                                         Tel: +44 (0) 1606 545508

Chris Meredith, Chief Operating Officer

Mary Tavener, Finance Director


Tavistock Communications

John West / Andrew Dunn / Chris Munden                                                Tel: +44 (0) 20 7920 3150



Notes to Editors:


AMS advanced woundcare products are based on an extensive range of technologies including alginates, silver alginates and hydrophilic polyurethane foam. These and other products pioneer the concept of moist wound healing, allowing wounds to heal faster and with less pain and scarring. They protect the wound, deal with tissue fluids and provide an optimal environment for healing to occur. The inclusion of silver adds a proven effectiveness against antibiotic resistant bacteria.


AMS wound closure and sealants products are based on cyanoacrylate adhesive (“superglue”) technology developed for medical applications. Tissue adhesives offer significant benefits over conventional ways of closing wounds following trauma or surgical incision. They are simple to use, non-invasive, help to reduce the risk of infection, minimise trauma to the patient and provide good clinical and cosmetic outcomes. The technology is also ideally suited to protecting skin from breakdown or for use as a skin sealant to help prevent infection of surgical sites.


AMS employs 240 people in three locations (Winsford, Plymouth and the Netherlands). In 2009, AMS delivered a 19% increase in revenues and a 51% increase in operating profit before exceptionals. The business has an experienced management team, whose stated aim is to grow the business both organically and by exploring selective acquisition opportunities. The Board has announced its intention to recommend a maiden dividend for the year ended 31st December 2010.


This information is provided by RNS
The company news service from the London Stock Exchange




For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.